Compare Citius Pharmaceuticals Inc (CTXR) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Fortinet Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Fortinet Inc trades at $168.41 (market cap $122.23B). The key difference: Fortinet Inc is far larger — about 8349× Citius Pharmaceuticals Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | FTNT | |
|---|---|---|
Market Cap | $14.64M | $122.23B |
Sector | Health | Technology |
52-Week High | $1.82 | $166.83 |
52-Week Low | $0.53 | $74.39 |
Enterprise Value | $10.86M | $119.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Fortinet (FTNT) trades at $160.62, up 1.97% on the day, with strong technical momentum and bullish moving averages. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.82 exceeding the $0.619 estimate. Revenue growth remains solid, reaching $6.80B in 2025, while high valuation ratios like a P/E of 62.26 reflect premium investor expectations. Recent news highlights expansion in AI-driven security solutions, positioning FTNT to capitalize on rising cybersecurity demand.
The outlook for FTNT is positive, driven by sustained demand for cybersecurity and AI integration, though elevated valuations and competitive pressures pose risks. Analyst consensus is mixed with 42.65% buy ratings, but the average price target of $121.11 suggests caution relative to the current price. Investors should monitor execution against raised 2026 guidance and industry spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
